SEARCH

SEARCH BY CITATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.

FilenameFormatSizeDescription
jcb24841-sm-0001-SuppMaterial.docx5678K

supporting informationFig. S1: Down-regulated miR-365 expression in vascular smooth muscle cells (VSMCs) treated with PDGF-bb and targets cyclin D1 (A) The effects of several miRNAs targeting cyclin D1 in VSMCs treated with PDGF-bb (20 ng/ml) and (B) transfection efficiency of miRs targeting cyclin D1 by realtime PCR. (C) Expression of cyclin D1 after transfection with miRs targeting cyclin D1 in VSMC were detected by western blot analysis. (*P<0.05 vs. control, #<0.05 vs. PDGF-bb-treated VSMCs).

supporting informationFig. S2: Effect of anti-miR-365 in VSMCs (A) Proliferation rate was analyzed by CCK assay after transfection with anti-miR-365 and treatment with PDGF-bb (20 ng/ml). (B,C) Expression of cyclin D1 and PCNA in VSMCs transfected with either N.C or anti-miR-365 were detected by western blot analysis (*P<0.05 vs. control).

supporting informationFig. S3: Effect of anti-miR-365 in migration of VSMCs. Analysis of cell migration as measured by a wound-healing assay. The cells were wounded with a 200 µl pipet tip and wound closure was photographed at 0 hr and 16 hr postwounding. Statistical analysis of the percent of wound closure (*P<0.05 vs. control).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.